Malaysian Journal of Medical Sciences
School of Medical Sciences, Universiti Sains Malaysia
Vol. 18, No. 4, 2011, pp. 58-62
Bioline Code: mj11053
Full paper language: English
Document type: Research Article
Document available free of charge
Malaysian Journal of Medical Sciences, Vol. 18, No. 4, 2011, pp. 58-62
© Copyright 2011 - Malaysian Journal of Medical Science
Neurodevelopmental Outcome of Newborns with Persistent Pulmonary Hypertension|
Rohana, Jaafar; Boo, Nem Yun; Chandran, Viji & Sarvananthan, Rajini
Background: Developmental disabilities have been reported in infants with persistent pulmonary hypertension of the newborn (PPHN) treated with inhaled nitric oxide (INO) or intravenous magnesium sulphate (MgSO4) and/or extracorporeal membrane oxygenation. This paper reports the rate of developmental disabilities at 2 years of age in a cohort of survivors of PPHN treated with INO, MgSO4, or both during the neonatal period.
Methods: Sixteen survivors of PPHN were prospectively followed up. These infants were treated with intravenous MgSO4 and/or INO during the neonatal period. Neurodevelopmental assessment was carried out at 2 years of age using the Bayley Scales of Infant Development 2nd Edition by a developmental psychologist. Eleven (68.8%) infants completed the 2-year follow-up.
Results: The median mental developmental index (MDI) and physical developmental index scores were 85 (interquartile range, IQR = 27) and 87 (IQR = 33), respectively. Two infants (18.2%) had developmental disability (MDI scores <70).
Conclusion: Survivors of PPHN are at risk of developmental disabilities. Early intervention programme and long-term follow-up should be integrated in the management of these infants.
developmental disabilities, magnesium sulphate, neurology, nitric oxide, persistent pulmonary hypertension of newborn
Alternative site location: http://www.medic.usm.my/publication/mjms/